Cyfuse

Basic Information

Stock Code
4892
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Tokyo
Establishment Year
August 2010
Listing Year
December 2022
Official Website
https://www.cyfusebio.com/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
GNI Group, Heartseed, Nexela Pharma, PeptiDream, SanBio, Helios, Fanpep, Perseus, RenaScience, QualiPS, Takara Bio, Japan Tissue Engineering, Glad C

Overview

Cyfuse is a bio-pharmaceutical company founded in 2010, innovatively developing regenerative medicine products using advanced 3D bioprinting technology.

Current Situation

Cyfuse primarily utilizes bio 3D printers to develop regenerative medicine products for peripheral nerves and tissues. As of 2023, it is in the clinical development stage, focusing on improving technical precision and establishing manufacturing processes for commercialization. It listed on the Tokyo Stock Exchange Mothers in 2022 to raise funds and is actively investing in technology development. Competitors include SanBio and Takara Bio, and it is strengthening its competitiveness through patent acquisition and deepening proprietary technologies. In terms of sustainability, it promotes social contributions through regenerative medicine and the development of sustainable medical technologies. In the future, it aims for product commercialization and market expansion, with plans to strengthen collaborations with medical institutions domestically and internationally. Recently, through collaboration with SCREEN Holdings, it has incorporated non-destructive inspection technology for cultured cells to advance quality control. Innovative technological advancements and business expansion are expected moving forward, positioning it as a pioneer in the bio industry.

Trivia

Interesting Facts

  • One of Japan's first companies to commercialize bio 3D printers
  • Holds numerous domestic patents for peripheral nerve regeneration technology
  • Achieved strategic technological collaboration with SCREEN Holdings
  • Listed on TSE Growth in a short period from venture company
  • Headquartered in Tokyo's medical bio cluster
  • Promoting quality management innovation with proprietary non-destructive inspection technology
  • Aiming to acquire international standards in regenerative medicine product manufacturing processes
  • Highly evaluated in the industry for developing special media for stem cell culture
  • Nerve regeneration gel has confirmed safety in multiple clinical trials
  • Researcher-led technological innovation is the core of company culture
  • Contributing to ecosystem formation for medical startups
  • Promoting industry-academia collaboration research with multiple universities
  • Actively deploying patent strategies with overseas market expansion in mind
  • Industry-renowned researchers appointed as executive officers
  • Non-invasive inspection technology highly evaluated domestically and internationally

Hidden Connections

  • Advancing inspection equipment development through technical partnership with SCREEN Holdings subsidiary
  • Joint research contracts with multiple domestic universities contribute to strengthening foundational technologies
  • Built close relationships with domestic and international pharmaceutical companies through patent licensing
  • Expanding regenerative medicine product market jointly with medical device manufacturers
  • Secured research subsidies in collaboration with government regenerative medicine promotion policies
  • Member of Japan Regenerative Medicine Industry Association, actively contributing to industry development
  • Achieved efficient clinical trials through partnerships with domestic CRO companies
  • Capturing market needs in nerve regeneration field in anticipation of aging society

Future Outlook

Growth Drivers

  • Expansion of regenerative medicine demand due to aging population
  • Global market expansion of bio 3D print technology
  • Promotion of medical practicalization of products through technological innovation
  • Accelerated market entry due to regulatory relaxation and legal framework development
  • Strengthened global expansion through international partnerships
  • Expanded product orders accompanying increased demand from medical institutions
  • Improved investment environment in regenerative medicine
  • Expanded product lineup to enhance treatment efficacy
  • Securing technical talent to strengthen competitiveness
  • High profitability accompanying maturation of biotechnology market

Strategic Goals

  • Obtain approval and practicalize regenerative medicine products domestically and internationally
  • Promote internationalization and dissemination of bio 3D print technology standards
  • Establish world leadership in quality management through non-destructive inspection technology
  • Build stable revenue base exceeding 30 billion yen in annual sales
  • Maximize social impact through sustainable medical technology development
  • Aggressively expand product deployment and partnerships in global markets
  • Strengthen innovative technology research through industry-academia-government collaboration
  • Expand in-house R&D teams and nurture diverse talent
  • Improve regulatory compliance and development speed in regenerative medicine
  • Innovate manufacturing processes through utilization of digital technology

Business Segments

Regenerative Medicine Product Development Support

Overview
Provides high-precision products and technologies specialized in research and development of regenerative medicine.
Competitiveness
Proprietary 3D bioprint technology and quality control
Customers
  • Pharmaceutical companies' R&D departments
  • Bio ventures
  • University medical research institutions
  • Regenerative medicine facilities
  • Public research institutes
  • Hospital clinical trial departments
  • Medical device manufacturers
  • Technology transfer departments of research institutions
  • Drug discovery research companies
  • Cell therapy facilities
Products
  • Bio 3D Printer
  • Cell Sheet Manufacturing Technology
  • Non-Destructive Cultured Cell Inspection Technology
  • Nerve Regeneration Gel
  • Cell Transplantation Scaffold
  • Tissue Repair Matrix
  • Cell Culture Auxiliaries
  • Bio Incubator

Medical Devices and Reagents Sales

Overview
Stable supply of equipment and reagents necessary for medical research and quality control.
Competitiveness
High-quality products and technical support system
Customers
  • Clinical testing facilities
  • Pharmaceutical companies
  • University hospitals
  • Research facilities
  • Medical equipment retailers
  • Bio research labs
  • Medical supply companies
  • CRO companies
Products
  • Cell Culture Medium
  • Gene-Related Reagents
  • Bio 3D Printer
  • Cultured Cell Inspection Device
  • Cell Culture Consumables

Joint Research and Technology Development

Overview
Promotes industry-academia collaboration research and development utilizing cutting-edge technologies.
Competitiveness
Technological innovation and patent accumulation
Customers
  • Pharmaceutical company research institutes
  • University research institutes
  • Technology venture companies
  • National research institutions
Products
  • 3D Print Technology Joint Development
  • Cultured Cell Inspection System
  • Joint Research on Regenerative Medicine Preparations

Clinical Trial Support Services

Overview
Undertakes clinical trials for regenerative medicine products and provides quality support.
Competitiveness
Specialized technology and high-precision inspection services
Customers
  • Pharmaceutical companies
  • Medical institutions
  • CRO companies
Products
  • Cell Quality Inspection
  • Production Process Quality Management
  • Bio Preparation Stability Evaluation

Quality Management Related Products

Overview
Provides equipment to support quality improvement in manufacturing processes.
Competitiveness
Pioneer in non-destructive technology
Customers
  • Pharmaceutical factories
  • Regenerative medicine manufacturing facilities
  • Research and development institutions
Products
  • Non-Destructive Cell Inspection Device
  • Cell Culture Monitoring Equipment

Culture Equipment and Consumables Supply

Overview
Provides necessary culture equipment and materials to support research environments.
Competitiveness
Product diversity and quality assurance
Customers
  • Regenerative medicine facilities
  • Research institutes
  • University ethics committees
Products
  • Cell Culture Vessels
  • Special Culture Additives
  • Sterilization Filters

Technology Licensing for Pharmaceutical Companies

Overview
Provides licenses for regenerative medicine technologies and technical support.
Competitiveness
Exclusive technology patent holdings
Customers
  • Domestic pharmaceutical companies
  • Overseas medical ventures
  • Bio pharmaceutical groups
Products
  • 3D Bioprint Technology License
  • Culture Technology Know-How

Education and Training Services

Overview
Educational support aimed at disseminating regenerative medicine technologies.
Competitiveness
Practical know-how and instructor team
Customers
  • Medical institutions
  • Universities
  • Bio-related companies
Products
  • Technical Training Programs
  • Regenerative Medicine Technology Seminars

Clinical Diagnostics Support

Overview
Deploys products that contribute to improving clinical testing accuracy.
Competitiveness
Application of cultured cell inspection technology
Customers
  • Hospital testing departments
  • Diagnostic drug manufacturers
Products
  • Cell Diagnostics Related Products
  • Inspection Reagents

Bioinformatics Support

Overview
Provides data analysis and consulting for the regenerative medicine field.
Competitiveness
Biological data analysis expertise
Customers
  • Research institutions
  • Pharmaceutical companies
  • Gene analysis providers
Products
  • Data Analysis Software
  • Technical Consulting

Patent and IP Management Support

Overview
Comprehensive IP services for technology protection.
Competitiveness
Expertise in regenerative medicine patents
Customers
  • Venture companies
  • Research institutions
  • Legal departments
Products
  • IP Management System
  • Technical Patent Registration Support

Domestic and International Partnerships and Fundraising Support

Overview
Supports partnership building and fundraising.
Competitiveness
Extensive industry network
Customers
  • New entrant companies
  • Bio R&D
  • Fund management departments
Products
  • Business Partnership Support
  • Investment Evaluation Advice

Competitive Advantage

Strengths

  • Advanced 3D bioprinting technology
  • High-quality management through non-destructive inspection
  • Technological uniqueness utilizing patents
  • Product lineup specialized in regenerative medicine
  • R&D capabilities based in Tokyo
  • Diverse industry-academia collaboration network
  • High technological capabilities and clinical application orientation
  • Fundraising power through TSE listing
  • Strengthened collaboration with SCREEN
  • Pioneering company in regenerative medicine

Competitive Advantages

  • Holds bio 3D printer patents domestically and internationally, establishing competitive superiority
  • Unique product lineup centered on peripheral nerve regeneration
  • Efficient quality inspection and improved product safety through non-destructive inspection technology
  • Improved customer satisfaction with integrated solutions of medical devices and reagents
  • Fast speed of technological innovation through industry-academia collaborations
  • Aims for market expansion through strategic partnerships with multiple related companies
  • High transparency and reliability as a listed company
  • Actively responding to increasing market needs in regenerative medicine
  • Improved market evaluation on TSE Growth
  • Maintaining competitiveness through continuous technological investment
  • Maintaining development capabilities by securing high-caliber technical staff
  • Established product development system directly linked to clinical applications
  • Accelerated product improvements through enriched in-house research facilities

Threats

  • Risk of strengthened regulations in regenerative medicine
  • Accelerating technological innovation speed by competitors
  • Rising fundraising costs and market fluctuations
  • Risk of commercialization delays depending on clinical trial results
  • Potential patent infringement litigation risks
  • Impact from international medical policy changes
  • Intensified market competition from new entrants
  • Time costs and market resistance until therapy adoption
  • Brand damage risk in case of quality issues
  • Fluctuations in imported material costs due to exchange rates
  • Supply chain disruptions due to global pandemics, etc.
  • Profit pressure from escalating R&D expenses

Innovations

2023: Introduction of Non-Destructive Cultured Cell Inspection Technology with SCREEN

Overview
Jointly developed technology enabling quality inspection of cultured cells without destruction.
Impact
Improved efficiency in quality management and reliability of manufacturing processes

2022: Development of New Bio 3D Printer Model

Overview
Achieved high-precision printing technology, significantly improving quality of regenerative medicine products.
Impact
Contributes to product uniformity and functional enhancement

2024: Initiation of Clinical Trials for Peripheral Nerve Regenerative Medicine Gel

Overview
Started clinical trials for proprietary biocompatible gel, approaching practical use.
Impact
Expected to expand treatment options in medical settings

2021: Development of Non-Invasive Bioengineering Monitoring Device

Overview
Developed device capable of externally monitoring cell culture status.
Impact
Improved quality stability during manufacturing

2023: Commercialization of High-Function Scaffold Materials

Overview
Began mass production of 3D printed materials specialized for cell growth and transplantation support.
Impact
Expanded regenerative medicine product lineup

Sustainability

  • Promoting reduction in use of animal-derived components
  • Implementing programs to reduce environmental impact in manufacturing processes
  • Contributing to reduction of societal medical burdens through regenerative medicine
  • Introducing sustainability standards in the supply chain
  • Emphasis on employee safety, health, and work-life balance